Immunovant Inc. (IMVT)

Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.

Immunovant, Inc. reported that positive results were achieved using batoclimab in a phase 3 study to target patients with Myasthenia Gravis; Primary endpoint met. Positive results achieved using batoc...

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The post Roivant, Immunovant Succeed In Phase 3.

Immunovant said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial.

Immunovant (IMVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisin...

Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.

The year started off slow as far as insider purchases go.